Sign up
Pharma Capital
Market: ASX
52-week High/Low: A$0.27 / A$0.10
Sector: Pharma & Biotech
Market Cap: A$36.55M

Regeneus Ltd (ASX:RGS) is a clinical-stage regenerative medicine company developing a portfolio of cell therapies with a focus on musculoskeletal disease, oncology and dermatology.

Regeneus Ltd

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in Regeneus Ltd

Regeneus Ltd Snapshot

Regeneus Ltd (ASX: RGS) is an Australian clinical-stage regenerative medicine company developing a portfolio of innovative cellular therapies targeting significant unmet medical needs with a licence driven strategy.

Roger Aston
Independent Chairman

Roger has served on the Board since 2013 and was appointed Chairman in November 2014. Roger is one of the most experienced and commercially astute people in drug commercialisation in Australia. Roger brings more than 20 years experience in the pharmaceutical and healthcare industries in senior roles in the UK, Asia Pacific and Australia. Roger is also a director or chairman on a number of boards carrying out late stage drug development.

John Martin

John has served on the Board as an Executive Director since early 2009 and was appointed CEO in November 2014. John has over 20 years of experience as a business executive, director and corporate lawyer including roles as CEO and director or ASX-listed and private emerging technology companies including BTF and Proteome Systems. John was a corporate and executive partner of Allens specialising in M&A, fundraising and life sciences.

Professor Graham Vesey
Executive Director

Graham is a co-founder and founding CEO of Regeneus and has served on the Board since incorporation. Graham was appointed Chief Scientific Officer in November 2014. Graham is a successful biotechnology entrepreneur, technology innovator and inventor and a highly regarded scientist. Graham was a co-founder and Executive Director or the successful biotech start-up, BTF, which was sold to bioMerieux in 2007. Graham is an Adjunct Professor at Macquarie University.

Barry Sechos
Non-Executive Director

Barry has served on the Board since 2012 and has over 20 years experience as a director, business executive and corporate lawyer with particular experience in investment and asset management. Barry is Executive Director of the Sherman Group (an early-stage investor in the Company) and sits on the Board of many Sherman Group companies and investee companies.

Dr Glen Richards
Non-Executive Director

Glen has served on the Board since April 2015. Glen practised companion animal medicine and surgery in Brisbane, Townsville and London before establishing Greencross Vets in 1994. As Managing Director of Greencross Ltd (ASX: GXL) he created Australia’s largest veterinary healthcare group with over 120 veterinary practices and 200 pet specialty stores. He resigned as MD of GXL in December 2014 and continues as a Non-executive Director. Glen is a Director of Smartvet Pty Ltd, a biotech company developing an innovative application of paraciticides for cattle. He is also a Non-executive Director of 1300smiles (ASX: ONT), an aggregator of dental facilities across Australia.

Leo Lee
Non-Executive Director

Leo has served on the Board since December 2017. Leo is a Senior executive with over 20 years of experience in Pharmaceutical innovation, commercialisation, regulatory and policy. He has worked in North America, Asia and has lived and worked in Japan the last 12 years. Leo was previously President of Allergan, Japan and former President of Merck Japan.


Last updated 16th July 2018

Email: [email protected]
Phone: +61 2 9499 8010

Street Address

Ground floor
25 Bridge Street
Pymble NSW 2073

ABN: 13 127 035 358

View full RGS profile View Profile
View All

Executive video interviews


© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.